Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Genitourinary 7Lymphoid 6Endocrine 6NET 5Breast 5Tumor-Agnostic 3Thoracic 3Head & Neck 3CNS 3Plasma cell 1Other hematologic neoplasm 1Gynecologic 1Classical hematology 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Positron Emission Tomography Computed Tomography × Plasma cell × Clear all
NCT03665155 2021-07-30

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
11 enrolled 11 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡